India halves clinical and marketing drug approval timelines, drops pre‑clinical clearance
Clinical trial sponsors get approvals in 120–135 days
Change
India's Drug Controller General of India (DCGI) reduced clinical trial approval times to 120–135 days, cut marketing authorisation reviews to under 150 days, and removed the requirement for regulatory approval at the pre‑clinical stage.
Why it matters
Regulatory review windows are now compressed, so submissions must be complete and defensible on first filing; incomplete or low‑quality dossiers will face rejection or lengthy re‑submission cycles. With no regulator‑issued pre‑clinical clearance, sponsors must internalise pre‑clinical compliance before seeking clinical approvals.
Implications
- — Regulatory affairs teams at pharmaceutical and biotechnology companies — must update submission timelines and ensure dossiers are complete immediately — incomplete filings will be processed within shorter review windows and risk rejection or protracted re‑submission delays.
- — Clinical trial sponsors and their contract research organisations (CROs) — must finalise protocols and submit regulatory documents now to meet accelerated review expectations — failure to align immediately will delay trial starts and extend time to market.
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer